|
Antibe Therapeutics Inc. - Reports
First Report of the Receiver
|
June 18, 2024 |
The purpose of this First Report is to provide information to the Court on the following:
(a) an overview of the Company, including the FDA Hold on the abdominoplasty clinical trial proposed by the Company;
(b) the Receiver's activities since the Date of Appointment;
(c) the Receiver's preliminary review of Nuance's Constructive Trust Claim;
(d) the proposed sale process (the "Sale Process"), including the engagement of Bloom Burton Securities Inc. as financial advisor to the Receiver to conduct the Sale Process with oversight from the Receiver, among other things, and the Receiver's motion for the granting of an order approving the Sale Process;
(e) the proposed Claims Procedure, and the Receiver’s motion for the granting of an order approving the Claims Procedure (the "Claims Procedure Order");
(f) the receipts and disbursements of the Receiver for the period from the Date of Appointment to June 7, 2024; and
(g) the Receiver's motion for an ancillary order (the "Ancillary Order").
|
|
|
|